Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  6.40 0.45% 1,416.00 3,445,960 16:35:24
Bid Price Offer Price High Price Low Price Open Price
1,417.60 1,418.20 1,419.20 1,406.40 1,408.60
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.00 6,221.00 93.90 15.1 71,240
Last Trade Time Trade Type Trade Size Trade Price Currency
17:36:23 O 62,500 1,413.00 GBX

Glaxosmithkline (GSK) Latest News (5)

More Glaxosmithkline News
Glaxosmithkline Investors    Glaxosmithkline Takeover Rumours
Smart Money!
GSK is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 BMO UK HIGH INCOME TRUST PLC 5.38% 2021-06-30

Glaxosmithkline (GSK) Discussions and Chat

Glaxosmithkline Forums and Chat

Date Time Title Posts
25/7/202109:14Glaxosmithkline - The recovery27,744
02/7/202110:58GSK - just mucking around-
22/2/202112:31GlazoSmithKline - News & Information43
23/1/202114:27In Rude Health!1

Add a New Thread

Glaxosmithkline (GSK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Glaxosmithkline trades in real-time

Glaxosmithkline (GSK) Top Chat Posts

Glaxosmithkline Daily Update: Glaxosmithkline Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Glaxosmithkline was 1,409.60p.
Glaxosmithkline Plc has a 4 week average price of 1,401.60p and a 12 week average price of 1,319.60p.
The 1 year high share price is 1,631.60p while the 1 year low share price is currently 1,190.80p.
There are currently 5,031,076,193 shares in issue and the average daily traded volume is 7,243,033 shares. The market capitalisation of Glaxosmithkline Plc is £71,240,038,892.88.
abdullla: GSK are busy trying to find a medication exclusively for you,so far they and us on this BB have not succeeded to cure you,could be reason to why the share price is going down
grahamite2: Hard work starts now for Glaxo, says Interactive Investor The hard work starts now for GlaxoSmithKline (GSK) after it confirmed the spin-off of its consumer healthcare business, says Interactive Investor. The group is planning to demerge 80% of its consumer healthcare division as part of a wide-ranging five-year plan that includes growing sales more than 5% and profit more than 10%. It also wants to deliver sales of over £33bn, prioritise research and development, and commercial investment in vaccines and specialty medicines under chief executive Emma Walmsley. Analyst Richard Hunter said the plans were ‘undeniably ambitious’ but it was not certain they would create an ‘inflection point’ for the shares. ‘Following a strategic reset, the hard work arguably starts here,’ he said. ‘AstraZeneca (AZN) is for the moment significantly preferred in terms of the market consensus, coming in at a strong ‘buy’. Glaxo, meanwhile, remains a ‘hold’ in terms of the general view and has much ground to make up to reverse the years of what has been a tepid share price performance.’ Shares in Glaxo edged up 0.2%, or 2.2p, to £14.13 on Friday. Https://;utm_medium=BulkEmail_FundsInsider+DawnChorus&utm_campaign=BulkEmail_FundsInsider+DawnChorus#i=3
abdullla: With all the excitement now gone GSK share price will go up and down all day long,wheels on the bus................
cyberian: Vaccine market could open up really big for GSK, with winter flu and other new variants of the Covid-19 likely over the next few years, and remember some pharmas are currently providing Covid-19 vaccine at cost. Other new medicines may well assist countries to manage with new pandemic break-outs, and again GSK may well have some near term solutions to help. I take the presentation as modestly positive, and would add on any shift lower in the share price as may well happen.
marktime1231: To sum up today's events, Old GSK is to become New GSK doing drugs and demerge New Consumer Healthcare selling toothpaste. Old GSK with about £34B revenues pays what everyone thinks is an unsustainable 80p dividend. New GSK will offload debt to New CH and use the capital boost to drive growth up to £33B revenues by 2031 paying a progressive dividend starting at 43p in FY23. New CH will have sales of about £10B but will be carrying extra debt, and will pay tbd dividend, maybe around 10p? Or get bought up. Do I get shares in both New GSK and New CH, what is the tax-efficient restructuring plan ... and am I happy with this strategy, is the growth plan exciting enough, deliverable, is it worth holding for the divis until demerger mid 2022? (Answers on a postcard please)
geckotheglorious: Interesting day... Linked for people's perusal, no interest either way myself. From II "GlaxoSmithKline: aggressive growth to compensate for dividend cut" Reaction to Glaxo’s eagerly awaited strategy update has been largely positive despite bad news for income seekers. GlaxoSmithKline GSK 1.03% shareholders are to see a 31% cut in dividend income as the drugs giant embarks on its strategy for delivering a “step-change” in growth in the next decade. The Glaxo divi is one of the most prized in the FTSE 100 index, having been at 80p a share since 2014 for a current yield of 5.7% and pay-out ratio representing 80% of forecast earnings. It will be reduced in 2022 for the first time in the 21 years since the merger of Glaxo Wellcome and SmithKline Beecham, as chief executive Dame Emma Walmsley (pictured) looks to focus resources on ways to remedy the company's lacklustre share price performance. In exchange for the dividend re-set, shareholders were today promised annual sales growth of more than 5% and operating profit growth of 10% between 2021 and 2026. Dame Emma's overall ambition is sales of £33 billion by 2031 as Glaxo prioritises investment around vaccines and speciality medicines in oncology, HIV and hard-to-treat diseases. City investors applauded the plans, although today's 3% rise in share price to 1,439p still only takes the company back to levels last seen in November. The guidance for a dividend of about 55p next year includes a final contribution from the consumer healthcare division being demerged next year. The remaining “New GSK” business is expected to adopt a progressive dividend policy targeting a pay-out ratio equivalent to about 40%-60%, starting with 45p a share in 2023. The planned 31% reduction to 55p equates to a yield of 3.9%, with the subsequent 45p for the New GSK business yielding 3.2%. interactive investor’s head of equities Richard Hunter said: “Even at the lower levels, the yields remain relatively attractive given the current interest rate backdrop. “By rebasing the dividend, this gives the company some flexibility towards achieving its new progressive policy, while also freeing up capital to help finance its wider ambitions to invest in the company’s product pipeline.” Glaxo will demerge 80% of its majority stake in the Sensodyne and Panadol consumer joint venture to Glaxo shareholders, with the new shares set for a premium listing in London. The separation of a business that generated annual sales of more than £10 billion last year should take place by the middle of 2022 and lead to an £8 billion windfall payment to New GSK. The narrower focus will enable New GSK to further enhance an existing pipeline of 20 vaccines and 42 medicines, many of which it says are potential best or first in class opportunities. Glaxo in a better place Dame Emma believes the company is now much better placed than when she was appointed chief executive in 2017, having overseen a “huge transformation” that has included the strengthening of R&D and improvements in commercial execution. She added: “We are now ready to deliver a step-change in growth for New GSK and unlock the value of Consumer Healthcare. “New GSK is exceptionally well positioned to positively impact people's health and to deliver strong performance and value to shareholders through the decade." Having set out her strategy for improving Glaxo's performance, attention will now turn to the reaction of activist investor Elliott Management. Little is known about Elliott's intentions towards Glaxo after it bought a significant stake earlier this year. However, it should be remembered that Elliott was in the background when rare disease specialist Alexion Pharmaceuticals sold itself to AstraZeneca for $39 billion in December. New York-based Elliott first took a stake in Alexion in 2017 and spoke out last May in opposition to the chief executive's plan to diversify its research pipeline, adding that the company should be considering an outright sale hTTps://
xxxxxy: GlaxoSmithKline (GSK.L) CEO Emma Walmsley will be updating shareholders on the company's strategy later on Wednesday and she is sure to be grilled about many issues, not least activist shareholder Elliot Management's stake.The company's shares dipped 1.5% ahead of the meeting, expected to start at 2pm BST.Elliot has been building up a multi-billion-pound stake in the pharma giant and Steve Clayton, manager of the HL Select UK Income Shares fund, which has a position in GSK, earlier said: "Elliot have a reputation for shaking up underperforming businesses and driving strategic change."Shareholders can also definitely expect an update on the company's plans to separate its consumer arm next year.Read more: GSK profit takes a hit amid COVID as activist fund builds up stakeEarlier, Walmsley had said: "Separation plans are well underway and we look forward to sharing our strategy and growth outlook for New GSK with investors in June."Nicholas Hyett, equity analyst at Hargreaves Lansdown, told Yahoo Finance UK: "My main focus in today's meeting is the decision on whether to spin off or IPO the consumer business. "There are good reasons for both approaches, but also reasons why certain groups of investors might reject both – it will make for a difficult juggling act for Walmsley."GSK is also under investor pressure as it lags behind in the coronavirus vaccines race compared with rivals such as AstraZeneca (AZN.L).Walmsley is likely to have to explain why "one of the world's premier vaccine makers was not in the front line in the war on COVID", the BBC said.She will reportedly admit that the company has been eclipsed by AstraZeneca, Pfizer (PFE) and others but that the pandemic is not over and GSK could still catch up.?GSK's share price was under pressure on Wednesday morning. Chart: Yahoo Finance UKGSK is expected to announce the results of trials of the vaccine it has developed with French company Sanofi in the coming months.Another question she will need to provide clarity on, according to The Times, is: "Can GSK develop a drugs pipeline capable of generating growth and offsetting looming generic competition?"GSK's profit took a hit in the first quarter of 2021, another concern shareholders are likely to have.The company said it saw strong growth in new pharmaceutical products, but that this was offset by stocking and pandemic disruption. It was also hurt by reduced patient visits to GPs and a muted colds and flu season as people wear masks and remain indoors, curbing their chances of catching a virus.Adjusted operating profit fell 30% in the period to £1.9bn ($26bn), while turnover was £7.4bn, down 18%... Yahoo Finance
spyder: Can you imagine how uncomfortable the Board will be when the Q&A starts at the end of tomorrow’s presentations and the share price has tanked? The stock market is a brutal appraiser, it will provide a real-time assessment of the presentation. I’m relaxed however because if the presentation flops and the share price tanks, then the Board will have lost all credibility and a breakup will be inevitable.
grahamite2: New GSK plans are ‘underappreciated’, says Liberum A part-initial public offering (IPO) of the consumer division of GlaxoSmithKline (GSK) looks increasingly likely, says broker Liberum. Analyst Alistair Campbell reiterated his ‘buy’ recommendation and target price of £17 on the pharmaceutical giant, which closed up 1.3%, or 19p, at £14.36 on Wednesday. The group will next week host an event called ‘New GSK’ that will set out the growth aspirations for the business after the consumer division has been hived off. ‘We forecasts sales growth of 6% per annum and earnings growth of 10% per annum for 2021-26, both a touch ahead of consensus,’ said Campbell. ‘GSK will also clarify the consumer separation plan, with debate as to whether this will be a spin-off or IPO. A part-IPO looks increasingly likely, particularly if GSK wants to invest in the pipeline.’ Campbell said this structure may add ‘further uncertainty to the process’, but over the long-term the potential for ‘New GSK is underappreciated’. Https://;utm_campaign=BulkEmail_FundsInsider+DawnChorus#i=2
xxxxxy: Drug-making giant GlaxoSmithKline today announced a $2 billion tie-up with a US-based biotech to strengthen its lacklustre drugs pipeline in advance of a long-awaited corporate split.The group said the deal with Boston-based iTeos Therapeutics will place its pharma and vaccines arm at the forefront of research into next-generation treatment for a range of cancers.Under the deal, worth $625 million upfront with another $1.45 billion in milestone payments, the two companies will co-develop and market a monoclonal antibody which targets part of the immune system - known as checkpoint CD226 - to help the body fight tumours.It is the latest of more than 20 buy-ups and partnerships announced in the past 12 months as GSK shores up cancer and vaccine research, before cleaving its pharma and consumer divisions into two separate companies.The announcement follows a bruising weekend of briefings which saw insiders attempt to pin blame for GSK's "flat-footed" Covid-19 vaccine response - compared to that of FTSE 100 rival AstraZeneca - onto CEO Dame Emma Walmsley.Some shareholders say it has solidified doubts over whether Walmsley, who lacks a strong science background, should lead the new pharma company as planned.But her supporters respond that the £70 billion supertanker of a company she inherited in 2017 will take at least a decade to turn around, a process that is now apace after four years at the helm.Either way, there is pressure to impress investors - including famously aggressive US hedge fund Elliott Management which has built up a multibillion-pound stake - at a capital markets day on June 23, when details of next year's split will be formally unveiled.It will be its biggest restructuring since Glaxo Wellcome merged with SmithKline Beecham in 2000 to create the company in its present form.And with shares down around 15% over Walmsley's four-year tenure, much is riding on deals such as the one announced today.GSK said the tie-up will make it the only pharma company with access to antibodies that block all three known cancer checkpoints at the key CD226 axis.It already partners with genetic testing company 23andMe and Surface Oncology on the two others, CD96 and PVRIG.The TIGIT inhibitor being developed by iTeos - which went public on the Nasdaq last summer with a $200million valuation - completes the set.Researchers will deploy different combinations of treatments against the three targets, each of which can turn the immune system off and prevent it from fighting cancer, to evaluate their effectiveness against multiple cancers.GSK chief scientific officer Dr Hal Barron said immuno-oncology - the science of harnessing a patient's immune system to fight tumours - had transformed cancer care but less than 30 percent of patients respond to treatment with existing checkpoint inhibitors.He said: "Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer."We are excited to collaborate with the team at iTeos and together we can play a leading role in the next generation of immuno-oncology therapies."The group, which employs 94,000, has had relatively few blockbuster launches of late and relies on its existing portfolio of products, of which 14 will lose their patents in the next decade.But latest analysis suggests there are more than 20 assets in its late-stage pipeline which could hit the market by 2026.Michel Detheux, president and CEO, iTeos said: "Through this transformative collaboration, iTeos now has access to GSK's best-in-class resources which will provide us with a significant advantage in a highly competitive, global market."Shares in iTeos shot up 50% in pre-market trading on the Nasdaq. Having risen and fallen sharply since the launch at $19 last July jumped 48.2% to $29.69c.GSK's share price continued their upward trajectory this month, up 7p or 0.5%, to 1410.4p..... Yahoo Finance
Glaxosmithkline share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210726 01:28:45